Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

The company’s market value was nearly cut in half following trial results showing higher rates of treatment discontinuations ...

As China rises and other global cities aggressively court biotech talent, Massachusetts faces a "contracting moment" that has ...